Andrew Berchuck
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Institute for Genome Sciences and Policy
Duke University Medical Center
USA
Name/email consistency: high
- Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Berchuck, A., Iversen, E.S., Luo, J., Clarke, J.P., Horne, H., Levine, D.A., Boyd, J., Alonso, M.A., Secord, A.A., Bernardini, M.Q., Barnett, J.C., Boren, T., Murphy, S.K., Dressman, H.K., Marks, J.R., Lancaster, J.M. Clin. Cancer Res. (2009)
- Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. Berchuck, A., Schildkraut, J.M., Pearce, C.L., Chenevix-Trench, G., Pharoah, P.D. Adv. Exp. Med. Biol. (2008)
- Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Berchuck, A., Iversen, E.S., Lancaster, J.M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H.K., Febbo, P.G., West, M., Nevins, J.R., Marks, J.R. Clin. Cancer Res. (2005)
- Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Berchuck, A., Iversen, E.S., Lancaster, J.M., Dressman, H.K., West, M., Nevins, J.R., Marks, J.R. Am. J. Obstet. Gynecol. (2004)
- Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Berchuck, A., Schildkraut, J.M., Wenham, R.M., Calingaert, B., Ali, S., Henriott, A., Halabi, S., Rodriguez, G.C., Gertig, D., Purdie, D.M., Kelemen, L., Spurdle, A.B., Marks, J., Chenevix-Trench, G. Cancer Epidemiol. Biomarkers Prev. (2004)









